3′ End Processing of the Prothrombin mRNA in ThrombophiliaDanckwardt S. · Hartmann K. · Gehring N.H. · Hentze M.W. · Kulozik A.E.
aDepartment of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, bEMBL – University of Heidelberg Molecular Medicine Partnership Unit, cEuropean Molecular Biology Laboratory, Heidelberg, Germany
Clinical and genetic studies have led to the discovery of specific genotypes that predispose to thromboembolism in adults and children. The exploration of the underlying pathologies has revealed a broad variety of affected molecular mechanisms. Most recently, the functional analysis of the prothrombin (F2) 20210*A variant revealed increased efficiency of 3′ end processing as a novel genetic mechanism predisposing to human disease. Here, we review the 3′ end processing of the human F2 mRNA and demonstrate how clinically relevant mutations in the F2 gene contribute to thrombophilia by interfering with a tightly balanced architecture of noncanonical 3′ end formation signals.
Andreas E. Kulozik
Molecular Medicine Partnership Unit, Im Neuenheimer Feld 153
DE–69120 Heidelberg (Germany)
Tel. +49 6221 564555, Fax +49 6221 564559
Number of Print Pages : 6
Number of Figures : 3, Number of Tables : 0, Number of References : 47
Vol. 115, No. 3-4, Year 2006 (Cover Date: March 2006)
Journal Editor: Ben-Bassat, I. (Tel Hashomer)
ISSN: 0001–5792 (print), 1421–9662 (Online)
For additional information: http://www.karger.com/AHA